Loading...

Home
ETF
CAPR

CAPR

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

CAPR News

Analysts Bullish on Capricor's Treatment Prospects

Mar 13 2026stocktwits

CAPRICOR THERAPEUTICS INC: B. RILEY INCREASES TARGET PRICE FROM $50 TO $63

Mar 13 2026moomoo

CAPR Stock Poised for Strongest Weekly Performance in Almost a Month: CEO Asserts 'No Chance' of Deramiocel Receiving Just Conditional Approval

Mar 13 2026stocktwits

Capricor (CAPR) Q4 2025 Earnings Call Transcript

Mar 13 2026NASDAQ.COM

Capricor Therapeutics Q4 2025 Earnings Call Insights

Mar 13 2026seekingalpha

Capricor Reports Loss, Awaits FDA Decision on Deramiocel

Mar 13 2026stocktwits

Capricor Therapeutics Reports Q4 Earnings Miss

Mar 12 2026seekingalpha

Capricor's New Therapy Shows Heart Function Improvement

Mar 12 2026stocktwits

Investigation into Atkore and Others by Johnson Fistel

Mar 12 2026Globenewswire

Capricor Therapeutics to Announce Q4 Earnings on March 12

Mar 11 2026seekingalpha

Capricor Advances DMD Therapy with FDA Resubmission

Mar 10 2026stocktwits

U.S. Stocks Rise as NIO Reports Strong Earnings

Mar 10 2026Benzinga

Capricor Therapeutics Shares Surge on FDA Decision

Mar 10 2026Benzinga

Capricor Therapeutics Sees 17% Surge After FDA Agrees to Review Deramiocel

Mar 10 2026seekingalpha

Deramiocel Poised to Be First Therapy for DMD's Cardiac and Skeletal Issues

Mar 10 2026Newsfilter

Capricor Stock Jumps 11% Following FDA's Resumption of Review for Muscle-Wasting Drug

Mar 10 2026moomoo